{"database": "openregs", "table": "federal_register", "rows": [["2013-15250", "Draft Guidance for Industry on Expedited Programs for Serious Conditions-Drugs and Biologics; Availability", "Notice", "The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled \"Expedited Programs for Serious Conditions--Drugs and Biologics.\" The purpose of this draft guidance is to provide a single resource for information on FDA's policies and procedures related to expedited drug development and review programs. The following programs are intended to facilitate and expedite development and review of new drugs to address unmet medical need in the treatment of serious or life-threatening conditions (expedited programs): Fast track designation, breakthrough therapy designation, accelerated approval, and priority review designation.", "2013-06-26", 2013, 6, "https://www.federalregister.gov/documents/2013/06/26/2013-15250/draft-guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics", "https://www.govinfo.gov/content/pkg/FR-2013-06-26/pdf/2013-15250.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled \"Expedited Programs for Serious Conditions--Drugs and Biologics.\" The purpose of this draft guidance is to provide a single resource for...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2013-15250"], "units": {}, "query_ms": 0.8820669900160283, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}